Navigation Links
Cepheid Reports 2013 First Quarter Results
Date:4/18/2013

IP) Transaction.  The Company excluded a tax benefit related to an intercompany IP transaction from its results for non-GAAP net loss for the first quarter ended March 31, 2012.  The Company excluded this item as it believes it is non-recurring in nature, and does not have a direct impact on the operation of the Company's core business. 

Forward-Looking StatementsThis press release contains forward-looking statements that are not purely historical regarding Cepheid's or its management's intentions, beliefs, expectations and strategies for the future, including those relating to potential growth, future revenues and future net income/loss and profitability, including on a non-GAAP basis, and test menu expansion and utilization. Because such statements deal with future events, they are subject to various risks and uncertainties, and actual results could differ materially from the Company's current expectations. Factors that could cause actual results to differ materially include risks and uncertainties such as those relating to: our ability to successfully complete and bring on line additional manufacturing lines; our success in increasing direct sales and the effectiveness of our sales personnel; the performance and market acceptance of new products; sufficient customer demand; our ability to develop new products and complete clinical trials successfully in a timely manner for new products; uncertainties related to the FDA regulatory and European regulatory processes; the level of testing at clinical customer sites, including for Healthcare Associated Infections (HAIs); the Company's ability to successfully introduce and sell products in clinical markets other than HAIs; the rate of environmental biothreat testing conducted by the USPS, which will affect the amount of consumable products sold to the USPS; variability in systems placements and reagent pull-through in the Company's HBDC program and the level of sales through that program; oth
'/>"/>

SOURCE Cepheid
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Testing Positive for Stability & Growth - Research Report on CombiMatrix Corporation, Cepheid, PerkinElmer, Inc., Life Technologies Corp. and Laboratory Corp. of America Holdings
2. Cepheid Announces Board of Directors Changes
3. Cepheid Reports 2012 Second Quarter Results
4. Cepheid Receives FDA Clearance for GeneXpert Infinity-80 System for Initial Use with Xpert Flu Assay
5. Cepheid Announces European Release of Xpert CT/NG and Xpert CT, Delivering Rapid Detection and Differentiation of Chlamydia and Gonorrhoeae
6. Diagnostic Marketing Association Names Cepheid 2011 Marketer of the Year
7. Cepheid Receives Grant to Develop Sample Processing and Amplification Methods for Detection of Bloodstream Bacteria
8. Cepheid to Webcast Upcoming Financial Presentations
9. Cepheid Reports Fourth Quarter and Full Year 2011 Results
10. Cepheid Welcomes Senior Vice President of Human Resources
11. Global Nano-Materials Market 2002-2016: Nano-Materials Industry, Production Volumes, Revenues and End User Market Demand - MarketResearchReports.Biz
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... NASA astronaut Scott Kelly , who is ... a year living and working on the International Space Station, ... 7 a.m. EDT Monday, March 9. Kelly will ... the final weeks of his training. The interviews will be ... highlighting his mission training and previous spaceflights. To ...
(Date:3/3/2015)... TORONTO , March 3, 2015 /CNW/- SQI Diagnostics ... and commercializes proprietary technologies and products for advanced ... Ryer CPA, CA, CFE  to its Management team. ... the Company in its transition from a development ... financing initiatives to advance the Company,s capital market ...
(Date:3/3/2015)... Fried, Frank, Harris, Shriver & Jacobson LLP ... joined the Firm as a partner in the Intellectual ... York office. Mr. Lewis concentrates on patent ... other intellectual property and general litigation. A trained chemical ... plaintiffs and defendants in a range of technology-related sectors ...
(Date:3/3/2015)... , March 3, 2015  Rosa & Co. ... drug-disease modeling and simulation research, today announced it has ... American Society for Clinical Pharmacology and Therapeutics meeting in ... 2015.   Logo - http://photos.prnewswire.com/prnh/20150302/179058LOGO   ... will present a poster describing a quantitative systems pharmacology ...
Breaking Biology Technology:NASA Astronaut Scott Kelly Available for Interviews before One-Year Space Station Mission 2SQI Diagnostics Appoints Chief Financial Officer 2SQI Diagnostics Appoints Chief Financial Officer 3Leading Patent Attorney Jeffrey Lewis Joins Fried Frank's Intellectual Property Litigation Practice 2Leading Patent Attorney Jeffrey Lewis Joins Fried Frank's Intellectual Property Litigation Practice 3Rosa & Co. Announces Two Poster Presentations at the American Society for Clinical Pharmacology and Therapeutics 2015 Annual Meeting 2Rosa & Co. Announces Two Poster Presentations at the American Society for Clinical Pharmacology and Therapeutics 2015 Annual Meeting 3
... for, Therapeutic Radiology and Oncology (ASTRO) meeting in Boston, September ... ... Booth # 547 -- Varian,Medical Systems (NYSE: VAR ), world leader ... full,spectrum of technologies and products for planning and delivering fast,precise cancer treatments ...
... of Oral Calcitonin, a,combination of Salmon Calcitonin and ... KNOLLS, N.J., Sept. 22 Emisphere,Technologies, Inc. (Nasdaq: ... AG,and Nordic Bioscience have completed recruitment for a ... of an oral formulation of,salmon calcitonin using Emisphere,s ...
... 22 Kiadis Pharma announced today,that its lead ... by the European Medicines Agency (EMEA) for the ... an allogeneic bone marrow,transplantation., "Following the orphan ... lead,product ATIR(TM), this is another important milestone in ...
Cached Biology Technology:Varian Medical Systems Exhibits a New Version of RapidArc(TM) Radiotherapy Technology and Other Products for Fast, Precise Cancer Treatment 2Varian Medical Systems Exhibits a New Version of RapidArc(TM) Radiotherapy Technology and Other Products for Fast, Precise Cancer Treatment 3Varian Medical Systems Exhibits a New Version of RapidArc(TM) Radiotherapy Technology and Other Products for Fast, Precise Cancer Treatment 4Emisphere Announces Recruitment Phase III Study for Oral Osteoarthritis Treatment 2Emisphere Announces Recruitment Phase III Study for Oral Osteoarthritis Treatment 3EMEA Grants Kiadis Pharma Lead Product ATIR(TM) Orphan Drug Designation 2
(Date:2/5/2015)... TRIANGLE PARK, N.C. , Feb. 5, 2015 /PRNewswire/ ... a specialist logistics company and has launched a new ... only Clinical Logistics Organization (CLO).  The new campaign focuses ... emphasis on patient, protocol and shipments. The ... First , aligns Marken,s priorities with its client,s ...
(Date:2/5/2015)... , Jan. 28, 2015 NXT-ID, Inc. ... the "Company"), a biometric authentication company focused on the ... the upcoming RedChip Global Online CEO Conference on January ... Gino Pereira , CEO of NXT-ID will ... lead product, the Wocket smart wallet and its full ...
(Date:1/22/2015)... Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is pleased to inform ... State of Washington,s Department of Licensing, in the ... issuance system for driver,s licenses and identification cards to its ... development will start in January 2015, with enrollment and card ...
Breaking Biology News(10 mins):Marken Launches New Patient-Centric Campaign 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3Valid USA Signs Contract For Washington Driver's License Issuance 2
... from the Virginia Bioinformatics Institute (VBI) at Virginia Tech ... a large family of virulence proteins that play an ... the plant pathogen Phytophthora sojae. VBI Professor ... with researchers from Virginia Techs Department of Plant Pathology, ...
... Gel-like material shows promise as oral insulin ... report development of a gel-like material that could help speed ... a pill by mouth, rather than with injections. The study ... a monthly journal. In the report, Nicholas A. Peppas ...
... Software Is Force Multiplier for Shelbyville Police ... BIO-key International,Inc. (OTC Bulletin Board: BKYI), a ... safety solutions, today announced the,award of a ... for the Department,s first mobile data system. ...
Cached Biology News:American Chemical Society's Weekly PressPac -- April 16, 2008 2American Chemical Society's Weekly PressPac -- April 16, 2008 3American Chemical Society's Weekly PressPac -- April 16, 2008 4American Chemical Society's Weekly PressPac -- April 16, 2008 5American Chemical Society's Weekly PressPac -- April 16, 2008 6American Chemical Society's Weekly PressPac -- April 16, 2008 7American Chemical Society's Weekly PressPac -- April 16, 2008 8BIO-key(R) Receives New Mobile Data Contract Award From Indiana Police Agency 2BIO-key(R) Receives New Mobile Data Contract Award From Indiana Police Agency 3
... Kit is an in vitro enzyme ... of human Gla-OC in serum, cultured ... other biological fluids. This kit ... is not for use in diagnostic ...
Human Aminopeptidase P2/XPNPEP2 Affinity Purified PAb ENTREZ GeneID: 7512...
... strains are K-12 derivatives that have mutations ... glutathione reductase (gor) genes, which greatly enhances ... have shown that expression in Origami(DE3) yielded ... host even though overall expression levels were ...
... All serum is extensively ... release criteria. All horses ... Diet and worming are controlled ... to lot consistency. Pricing: ...
Biology Products: